A Single Center, Open-label, Non-comparative, Phase I/II Clinical Trial to Assess the MTD, Safety and Efficacy of BEY1107 in Monotherapy and in Combination With Gemcitabine in Patient With Locally Advanced or Metastatic Pancreatic Cancer
Phase of Trial: Phase I/II
Latest Information Update: 18 Sep 2019
Price : $35 *
At a glance
- Drugs BEY-1107 (Primary) ; Gemcitabine (Primary)
- Indications Adenocarcinoma; Pancreatic cancer
- Focus Adverse reactions; Therapeutic Use
- Sponsors BeyondBio
- 23 Jul 2019 Planned End Date changed from 13 Oct 2021 to 1 Oct 2021.
- 23 Jul 2019 Planned primary completion date changed from 23 Mar 2021 to 1 Mar 2021.
- 16 Jul 2018 New trial record